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Abstract
Malignant melanoma is one of the most aggressive types of tumor. Because malignant melanoma is difficult to treat once it
has metastasized, early detection and treatment are essential. The search for reliable biomarkers of early-stage melanoma,
therefore, has received much attention. By using a novel method of screening tumor antigens and their auto-antibodies, we
identified bullous pemphigoid antigen 1 (BPAG1) as a melanoma antigen recognized by its auto-antibody. BPAG1 is an
auto-antigen in the skin disease bullous pemphigoid (BP) and anti-BPAG1 auto-antibodies are detectable in sera from BP
patients and are used for BP diagnosis. However, BPAG1 has been viewed as predominantly a keratinocyte-associated
protein and a relationship between BPAG1 expression and melanoma has not been previously reported. In the present
study, we show that bpag1 is expressed in the mouse F10 melanoma cell line in vitro and F10 melanoma tumors in vivo and
that BPAG1 is expressed in human melanoma cell lines (A375 and G361) and normal human melanocytes. Moreover, the
levels of anti-BPAG1 auto-antibodies in the sera of melanoma patients were significantly higher than in the sera of healthy
volunteers (p,0.01). Furthermore, anti-BPAG1 auto-antibodies were detected in melanoma patients at both early and
advanced stages of disease. Here, we report anti-BPAG1 auto-antibodies as a promising marker for the diagnosis of
melanoma, and we discuss the significance of the detection of such auto-antibodies in cancer biology and patients.
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Introduction
Melanoma is one of the most aggressive tumors due to its strong
capacity to metastasize. In the United States, there were an
estimated 62,480 new melanoma cases and 8,420 deaths caused by
melanomas in 2008 [1]. Although the 5-year survival rate of
patients with early stage localized melanoma is greater than 90%,
survival rates drop to less than 20% once the melanoma has
metastasized to distant sites [1]. In general, early diagnosis of
cancers greatly improves the survival of patients. Therefore, great
efforts have been made to screen tumor markers for early
diagnosis. Several melanoma markers (e.g. gp100, MART-1 and
tyrosinase) have been detected and proposed for immunotherapy
approaches [2,3,4]. With regards to melanoma markers in serum,
S100 protein, 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-
2-carboxylic acid can be useful although levels tend to be more up-
regulated in advanced melanomas. As such, these particular
markers are not suitable for the early detection of malignant
melanoma [5]. Glypican-3 (GPC3), however, is overexpressed in
melanoma and its serum concentration can serve as an early stage
melanoma diagnostic marker [6,7]. Nevertheless, from a practical
prospective, use of only one biomarker may lack sensitivity and
specificity and diminish clinicopathologic value. The availability of
multiple markers would make the diagnosis of melanoma more
reliable, and thus there is a need to identify and assess additional
melanoma markers.
In the present study, we developed a screening method to detect
tumor markers recognized by auto-antibodies to these proteins in
serum. Using this method, we found that bullous pemphigoid
antigen 1 (BPAG1) was expressed in both melanoma cell lines and
normal melanocytes. BPAG1 is a plakin family protein that
anchors keratin filaments to hemidesmosomes [8]. Another
protein BPAG2, a transmembranous collagen, is also expressed
in the skin and is a component of hemidesmosomes [8]. Deletion
of the dst gene, that encodes bpag1, disrupts hemidesmosomes
structure, resulting in the failure of hemidesmosomes to associate
with keratin filaments [9]. Both BPAG1 and BPAG2 can serve as
auto-antigens in bullous pemphigoid (BP) [10,11,12]. Auto-
antibodies to BPAG1 and BPAG2 maybe detected in the sera of
BP patients, and assessment of antibody levels can be used for BP
diagnosis and clinical management. While passive transfer
experiments have shown that BPAG2 antibodies have pathogenic
relevance to BP, the clinicopathological significance of BPAG1
antibodies, has not yet been fully elucidated [13]. It has been
hypothesized that anti-BPAG1 auto-antibodies might interfere
with hemidesmosome integrity, but this has not been proven [9].
Here, we show that the level of auto-antibodies against BPAG1
in the sera of melanoma patients, at both early and advanced
PLoS ONE | www.plosone.org 1 May 2010 | Volume 5 | Issue 5 | e10566stages, was significantly higher than levels in the sera of healthy
volunteers. These findings identify anti-BPAG1 auto-antibodies as
a novel and promising tumor biomarker in the detection of
melanoma.
Materials and Methods
Libraries, bacteria and helper phage
The human single-fold scFv libraries I + J (Tomlinson I + J), E.
coli TG1 and HB2151, and KM13 helper phage were all kindly
provided by the Medical Research Council (MRC). The scFv
library was prepared as previously described [14]. The scFv library
was cloned into the pIT2 expression vector, which contains a lac
promoter and a pelB leader sequence upstream of the VH-(G4S)3-
VL insert; the insert is followed by 66His and myc tags, an amber
stop codon and the gene encoding the pIII phage coat protein.
Thus, in a suitable non-suppressor strain (HB2151), addition of
isopropyl-thio-b-D-galactoside (IPTG) induces only scFv and not
scFv–pIII fusion expression.
Mice
Female C57BL/6N mice (6 weeks old) were studied (Charles
River Laboratories Japan, Inc., Japan) Animal experiments were
performed in accordance with the guidelines of the Osaka
University Graduate School of Medicine.
Cell lines and culture
Mouse melanoma cell line F10, mouse fibroblast cell line NIH-
3T3, human melanoma cell lines A375, G361 and human
epidermoid carcinoma A431 were obtained from the American
Type Culture Collection (ATCC, USA). Normal human kerati-
nocyte (NHK) cells and melanocyte (NHM) cells were obtained
from Lonza (USA). F10, NIH-3T3, A375, G361 and A431 cells
were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) (Nacalai Tesque Inc., Japan). DMEM was supplemented
with 10% fetal bovine serum (FBS) (Biowest, France), 100 units/
ml penicillin and 0.1 mg/ml streptomycin (penicillin-streptomycin
mixed solution) (Nacalai). NHK and NHM cells were maintained
in keratinocyte growth medium (KGM) (Lonza) and melanocyte
growth medium (MGM-4) (Lonza), respectively.
Preparation of tumor lysates and the isolation of sera
from tumor-bearing mice
F10 cells (5610
6) were intradermally injected into the backs of
C57BL/6N mice. After 4 weeks, tumors were excised, and protein
was extracted using T-PER Tissue Protein Extraction Reagent
(Pierce, USA), according to the manufacturer’s instructions. At the
same time as the tumor excision, whole blood was collected, and
the sera were isolated using Capiject Capillary Blood Collection
Tubes (Terumo Corp., Japan).
In vivo screening of tumor-homing phages and isolation
of the tumor-binding scFv
F10 cells (5610
6) were intradermally injected into the backs of
C57BL/6N mice. After tumors reached 7 to 8 mm in diameter,
we injected the phage library (1610
13 CFU) dissolved in 100 ml
saline into the tail veins of tumor-bearing mice. After 15 min, the
animals were sacrificed by an overdose of anesthetic and perfused
via the heart with 100 ml of PBS [15]. Next, the tumor tissue was
snap-frozen in liquid nitrogen and homogenized in a mortar.
Tumor-homing phages were eluted by using 500 ml of 0.1 M
glycine (pH 2.2) for 15 min, and then the solution was neutralized
with 50 ml of 2 M Tris-HCl (pH 8). Next, 50 mL of Protein A (GE
Healthcare, USA) was added to the neutralized phage solution,
and the mixture was rotated for 1.5 h at 4uC. After washing with
PBS to remove unbound phages, phages bound to protein A were
used to infect log-phase HB2151 for 1 h at 37uC; then, the cells
were plated on 26YT agar plates containing 100 mg/ml
carbenicillin. After 16 h of incubation at 37uC, a nitrocellulose
membrane soaked in 100 mM IPTG (Takara Bio Inc., Japan) for
10 min was placed on the 26YT plate for 4 h at 37uC. The plate
was stored at 4uC as a master plate for E.coli recovery. The
membrane was washed 3 times with PBS containing 0.1% tween
20 and blocked 30 min with PBS containing 5% skim milk
(Nacalai). Then, the membrane was incubated with tumor lysate
followed by tumor-bearing mouse serum. The complexes of auto-
antibodies bound to tumor proteins were detected with the anti-
mouse IgG horseradish peroxidase-conjugated antibody (GE
Healthcare) followed by ECL Western Blotting Kit (GE
Healthcare).
Identification of tumor antigen with MALDI-TOF mass
spectrometry
Positive clones that were recovered from the stored 26YT agar
plate were re-plated onto a fresh 26YT agar plate and incubated
for 16 h at 37uC. Next, a nitrocellulose membrane soaked with
100 mM IPTG was placed onto the 26YT agar plate for 4 h at
37uC. After washing with PBS containing 0.1% tween 20, the
membrane was blocked 30 min with 0.5% polyvinylpyrrolidone
K30 (Nacalai), and then the membrane was incubated with
tumor lysate. The scFv-tumor protein complexes were stained
with 0.5% ponceau (Wako Pure Chemical Industries, Ltd.,
Japan)/5% acetic acid in distilled water, and the membrane
around the area was excised. The protein on the excised
membrane was digested with 100 ng/ml trypsin (Sigma-Aldrich,
USA)/40 mM ammonium bicarbonate (Nacalai) for 6 h at 37uC.
Then, the solution was dried up, and saturated a-cyano-4-
hydroxy cinnamic acid (Wako), 1% trifluoroacetic acid, and 50%
acetonitrile was added. After desalting with a ZipTip C18, the
solution was analyzed using an Ultraflex MALDI-TOF/TOF
instrument (Bruker Daltonik, Germany). The mass spectrometry
data were analyzed with the Mascot search engine (http://www.
matrixscience.com).
RT-PCR and real-time PCR
RNA was extracted using Isogen (Nippon Gene, Japan), and
1 mg of total RNA was converted to cDNA with SuperScript III
(Invitrogen, USA), according to the manufacturer’s instructions.
Mouse bullous pemphigoid antigen 1 (bpag1), TBC1 domain
family member 13 (tbc1d13), uncharacterized protein C7orf30
homolog (c7orf30), and b-actin were amplified using SYBR
Premix Ex Taq (Takara Bio) and an ABI Prism 7900 sequence
detector (Applied Biosystems, USA). Human BPAG1, BPAG2,
and b-actin were amplified with TaKaRa Ex Taq Hot Start
Version, and PCR products were analyzed by electrophoresis on
1% agarose gels. All procedures were performed according to the
manufacturer’s instructions.
The primers were as follows:
Mouse bpag1-f:59- TTGGAACAGACCTGGAGACC-39
Mouse bpag1-r:59- GTTCAGCCTTTCCATTTCCA-39
Mouse tbc1d13-f:59- AGGCCAACATGGGTGTATTC -39
Mouse tbc1d13-r:59- AGGGTTTGGGTTCAGAGGAT-39
Mouse c7orf30-f:59- GAGGGGAAGGACGCTGAC -39
Mouse c7orf30-r:59- TGGAAGCATCAAATGGATCA-39
Mouse b-actin-f:59- CCACTGCCGCATCCTCTTCC-39
Mouse b-actin-r:59- CTCGTTGCCAATAGTGATGACCTG -39
Human BPAG1-f:59- CCAGCCCGGTTAACTATTGA -39
BPAG1 Auto-Antibody
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Human BPAG2-f:59- GCTGGAGATCTGGATTACAATGA-39
Human BPAG2-r:59- CCTTGCAGTAGGCCCTGA-39
Human b-actin -f:59- GAGCTACGAGCTGCCTGACG-39
Human b-actin -r:59- GTAGTTTCGTGGATGCCACAG-39
Detection of BPAG1 by Immunoprecipitation (IP) and
Western blotting
Cells (1610
7) were trypsinized, washed in cold PBS and
resuspended in 500 ml RIPA buffer. IP of total cell lysates were
incubated with anti-BPAG1 antibody (sc-13776) (Santa Cruz
Biotechnology Inc., USA) or normal goat IgG (Santa Cruz) for 1 h
followed by protein G agarose (GE Healthcare) overnight. SDS-
PAGE and Western blotting were performed, as previously
described [16] with anti-BPAG1 antibody. After incubation with
HRP conjugated anti-goat IgG (R&D systems, USA), signals were
detected with ECL Western Blotting Detection Regents (GE
Healthcare) according to the manufacturer’s instructions.
Quantification of BPAG1 auto-antibodies in sera
Approval for this study was obtained from the Institutional
Review Board of the Osaka University Hospital (#08312). Written
informed consent was obtained from all participants before the
study. We collected sera from 55 melanoma patients and 27
healthy volunteers. The malignant melanoma patients studied
here consisted of 24 men and 31 women with an average age of
62.6 years (range, 22 to 86 years); 13 had stage 0 (in situ) or stage I;
5 had stage II; 11 had stage III; 26 had stage IV. The healthy
volunteers consisted of 15 men and 12 women with an average age
of 31.6 years (range, 24 to 49years). The sera samples were stored
at 230uC prior to use and the serum levels of anti-BPAG1 auto-
antibodies were determined using a BP230 ELISA kit (MBL,
Japan) according to the manufacturer’s instructions. The INDEX
was calculated as follows; INDEX = (sample absorbance –
negative control absorbance [INDEX=0])/(positive control
absorbance [INDEX=100] - negative control absorbance) 6100
[17]. The Mann-Whitney U test was used to determine statistical
significance, and p,0.05 was considered statistically significant.
Results
Identification of bpag1 as a tumor antigen recognized by
auto-antibodies
An overview of the screening procedure is shown in Figure 1.
We performed the screening on mouse F10 melanoma cell lines.
The tumor-homing phages were collected by in vivo biopanning in
tumor-bearing mice. The phages were used to infect HB2151 for
scFv expression and plated on a 26YT agar plate. After 16 h,
scFv expression was induced with IPTG, and the resulting scFvs
were transferred onto a nitrocellulose membrane. The membrane
was incubated with F10 melanoma tumor lysate followed by F10
tumor-bearing mouse serum. The scFv-tumor protein complexes
on the nitrocellulose membrane were detected with the auto-
antibodies in the serum collected from the tumor-bearing mice
(Figure 2A). We performed the screening procedure several times
and selected high-signal clones, distinct from background signals,
for further experiments. Next, we analyzed the proteins that were
detected with auto-antibodies by performing MALDI-TOF mass
spectrometry, and we identified 8 potential melanoma marker
candidates with statistical significance (p,0.05) (Figure 2B). The
candidates were ordered according to the expectation value,
which is the expected frequency of the matches to be obtained
from mass spectrometry merely by chance. We compared the
expression of the 8 candidates among NIH-3T3 cells, F10
melanoma cells and F10 melanoma tumors by real-time PCR.
Bpag1, tbc1d13 and c7orf30 were expressed at much higher
levels in F10 melanoma cells (7.0-, 3.1- and 1.9-fold, respectively)
and F10 melanoma tumors (10.9-, 4.2- and 6.3-fold, respectively)
as compared to NIH-3T3 cells (Figure 2C); the expression levels
of the remaining 5 candidates in melanoma cells and tumors were
less than the expression level in NIH-3T3 cells (data not shown).
Among the three candidates, we selected bpag1 for further
investigation because bpag1 was expressed most abundantly in
F10 melanoma cells and tumors, and is known to have a
restricted tissue expression pattern, including skin, brain and
muscle [18].
Differential expression of BPAG1 and BPAG2 in normal
human melanocytes and human melanoma cell lines
We used RT-PCR to confirm the expression of BPAG1 in
human melanomas. BPAG1 is expressed in normal human
keratinocytes and is a component of hemidesmosomes along with
BPAG2. Thus, we used normal human keratinocytes as a positive
control for both these proteins. We identified BPAG1 expression
in human melanoma cell lines (A375 and G361) and normal
human melanocytes (Figure 3A). However, we did not detect
BPAG2 expression in the human melanoma cell lines or normal
human melanocytes (Figure 3A). We also detected BPAG1 protein
in A375 and G361 by IP-western blotting (Figure 3B).
Quantification of anti-BPAG1 auto-antibodies in sera
Auto-antibodies against BPAG1 are found in sera from BP and
therefore BPAG1 maybe a highly immunogenic protein. We
hypothesized that the human immune system might generate auto-
antibodies against BPAG1expressed in human melanomas. To assess
this possibility, we collected sera from 55 melanoma patients and 27
healthy volunteers and quantified the serum levels of anti-BPAG1
auto-antibodies by ELISA (Figure 4A). The average (6S.E.M.)
INDEX value of the control group and the melanoma group was
1.64 (60.27) and 3.47 (60.40), respectively. We classified melanoma
patients as follows: in situ, stage I or stage II patients were ‘‘early’’
(n=18), and stage III or stage IV patients were ‘‘advanced’’ (n=37).
The levels of anti-BPAG1 auto-antibodies were much higher in both
early and advanced stage melanoma patients (p,0.01) as compared
to the healthy volunteers (Figure 4B). The average INDEX value
(6S.E.M.) for the early and advanced melanoma patients was 4.14
(60.83) and 3.15 (60.43), respectively. Next, we evaluated the
possibility of using anti-BPAG1 auto-antibodies as a melanoma
detectionmarker.ThemaximumINDEXvalueinhealthyvolunteers
(4.64) was defined as the cut off level. Applying these criteria, the
positive rates of serum anti-BPAG1 auto-antibodies were 23.6% in
total melanoma patients (13/55), 33.3% in early stage melanoma
patients (6/18), and 18.9% in advanced stage melanoma patients (7/
37) (Table 1). We also conducted indirect immunofluorescence
studies using 4 melanoma patients’ sera and demonstrated that IgG
antibodies produced in patients reacted with skin basement
membrane zone with variability in staining intensive (down to a
dilution of 1:160).
Discussion
In the present study, we developed a novel screening method for
detecting tumor biomarkers. Our method is similar to SEREX in
that we use serum containing anti-tumor auto-antibodies, but
unlike SEREX, however, our method does not require a cDNA
library from tumor tissue [19,20,21]. We anticipate that our
method has clinical applicability, because it can be applied to
human patients by modifying the method to select tumor-homing
BPAG1 Auto-Antibody
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The tumor-homing scFv-presenting phages were collected from tumors that were injected with a scFv library. The collected phages were infected to
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tumor-bearing mice, but it is also possible to use tumor specimens
[22]. Moreover, the phage screening could be conducted in
human cancer patients without any detectable toxicity [23]. This
method therefore has the potential to identify the most suitable
tumor antigens for diagnosis or vaccination.
Nevertheless, our method did not detect previously identified
melanoma antigens, such as gp100, tyrosinase, TRP-1 and TRP-2;
instead, it detected completely different proteins. Gp100, tyrosi-
nase, and TRP-2 were identified previously as melanoma antigens
recognized by cytotoxic T cells from cancer patients, and TRP-1
was identified as a melanoma antigen recognized by IgG
antibodies in the serum of a melanoma patient [24]. The epitopes
of these antigens can efficiently activate tumor immunity, and they
have been developed for cancer immunotherapy trials [25].
Although auto-antibodies to these melanoma antigens were
detected in the sera of melanoma patients, the antigens were not
frequently identified in sera from melanoma patients [26,27,28]. A
possible explanation might be that auto-antibodies to such
melanoma antigens exist in the sera of melanoma patients, but
lack sensitivity or are present at low titers. Proteins identified by
our screening method, however, have the potential to elicit the
production of auto-antibodies in tumor-bearing individuals. In
other words, our screening method may detect highly immuno-
genic proteins. Thus, it can be an effective tool for identifying
detection markers in serum.
Given the differences in immune systems between mice and
human, it is possible that the positive results screened in mice might
HB2151 for scFv secretion. The secreted scFvs from HB2151 were transferred to nitrocellulose membranes by colony lift. The membranes were
incubated with tumor lysate followed by serum from a tumor-bearing mouse. The scFv-tumor protein complex was detected by auto-antibodies. The
complex was digested into peptide by trypsin and analyzed using MALDI-TOF mass spectrometry for identification.
doi:10.1371/journal.pone.0010566.g001
Figure 2. Identification of bpag1 as a tumor antigen recognized by auto-antibodies. (A) An example of the screening output. ScFv-tumor
antigen complex was detected with auto-antibodies in tumor-bearing mouse serum. (B) Eight candidates were identified by MALDI-TOF mass
spectrometry with statistical significance (p,0.05); expect = expectation value. (C) Comparison of bpag1, tbc1d13 and c7orf30 expression in NIH-3T3
cells (white bar), F10 melanoma cells (black bar) and F10 melanoma tumors (grey bar) by SYBR Green real-time PCR.
doi:10.1371/journal.pone.0010566.g002
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antibodies need to be performed in human melanoma patients.
However, although the phage screening has been conducted in
human cancer patients without any detectable toxicity, the method is
still at a clinical trial stage [23]. It is therefore not yet straightforward
orpracticabletoconductphagescreeninginhumans.Withregardsto
our studies, screening mice also has the advantages of repeatability
and uniformity of samples. On the other hand, it is difficult toconduct
repeated screening in human cancer patients. Moreover, since the
background ofallthe murine samples is uniform in our screening, any
consistently positive result from repeated screenings will be highly
reliable as tumor markers. In contrast, since the tumor stages and
immunological states of patients are diverse, the results of screening
using human patient sera would need extensive re-validation work.
We also showed that BPAG1 is expressed in human melanoma
cell lines and that auto-antibodies against BPAG1 can be a potent
melanoma marker. BPAG1 is expressed in normal keratinocytes
within hemidesmosomes in association with BPAG2 and other
proteins [8]. We did not detect any BPAG2 expression in human
melanoma cell lines and melanocytes, and thus BPAG1 may have
distinct functions in melanomas and melanocytes. BPAG1 is also
expressed in some neurons and is involved in axonal neurofilament
aggregation and axonal microtubule disorganization [29,30]. The
expression of BPAG1 in a human epidermoid carcinoma cell line
(A431) and mammary ductal carcinoma in situ has also been
confirmed [31,32]. Thus BPAG1 may have an as yet undefined
role related to tumorigenesis or tumor progression; overexpression
and suppression of BPAG1 in melanocytes and melanomas will be
necessary to determine this in more detail.
Some patients with melanoma develop vitiligo-like white
patches, known as melanoma-associated hypopigmentation
(MAH), on their skin [33]. Interestingly, the presence of vitiligo
in melanoma patients may correlate with improved prognosis
[34,35]. Such patients with vitiligo could have more effective
immunity against melanoma than patients without vitiligo. In
general, the appearance of autoimmune phenomena improves the
outcome of cancer patients [36]. However, such autoimmune
phenomena are suppressed in most cancer patients by regulatory
T (Treg) cells [37]. Treg cells inhibit CD8
+ and CD4
+ T cells,
which are major components of cancer immunosuppression
[38,39]. The depletion of Treg cells from tumor-bearing mice
promotes tumor regression [38,39]. Interestingly, auto-antibodies
Figure 3. Expression of BPAG1 in normal human melanocytes and human melanoma cell lines. (A) The expression of BPAG1 and BPAG2
mRNA was quantified by RT-PCR in normal human melanocytes (NHM) and human melanoma cell lines A375 and G361. Normal human keratinocyte
(NHK) mRNA was used as a positive control. b-actin was amplified as a loading control for cDNA. NTC; no template control. (B) The expression of
BPAG1 protein was detected by IP-western blotting in human melanoma cell lines A375 and G361. A431 was used as positive control for BPAG1. The
arrow indicates BPAG1.
doi:10.1371/journal.pone.0010566.g003
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efficiency of Treg-cell depletion may correlate with the emergence
of auto-antibodies. Thus, the presence of anti-BPAG1 auto-
antibodies may correlate with the occurrence of autoimmune
responses in melanoma patients. By quantification of anti-BPAG1
auto-antibodies, it maybe possible to predict the immune status of
cancer patients. In theory, immunotherapy against melanoma,
therefore, might be more effective for patients with anti-BPAG1
auto-antibodies than those without antibodies.
We showed that BPAG1 is expressed both in melanocytes and
melanomas. Since BPAG1 expression is maintained throughout
the stages of melanoma tumorigenesis, BPAG1 auto-antibodies
can be created even in the early stage of melanoma. We showed
that the levels of anti-BPAG1 auto-antibodies are higher in
melanoma patients at both early and advanced stages than in
healthy volunteers (Figure 4 and Table 1). This result suggests that
anti-BPAG1 auto-antibodies can be present in early stage
melanoma, i.e. before it metastasizes. Thus, anti-BPAG1 auto-
antibodies have the potential to be a promising melanoma
biomarker. To test this hypothesis, we are planning to conduct a
larger clinical study.
To the best of our knowledge, this report is the first to show
BPAG1 expression in human melanomas and melanocytes and to
highlight the potential of anti-BPAG1 auto-antibodies in the serum
Figure 4. Quantification of anti-BPAG1 auto-antibodies in melanoma patients. (A) The levels of anti-BPAG1 auto-antibodies in sera
collected from healthy volunteers and melanoma patients were quantified using a MESACUP BP230 ELISA Kit. The INDEX values were plotted and the
average INDEX values as shown (6S.E.M.) for control subjects (1.6460.27) and melanoma patients (3.4760.40). (B) The melanoma patients were
classified using the American Joint Committee on Cancer (AJCC) 2002 staging criteria. In situ, stage I or stage II patients were categorized as ‘‘early’’,
while stage III or stage IV patients were categorized as ‘‘advanced’’. The average INDEX values (6S.E.M.) of early and advanced melanoma patients
were 4.1460.83 and 3.1560.43, respectively; the bars indicate the average INDEX value.
doi:10.1371/journal.pone.0010566.g004
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our screening method. Wewillcontinue to develop this method into a
moresophisticatedmethodthatcanbe used clinically. To validate the
use of anti-BPAG1 auto-antibodies for melanoma diagnosis, we need
to clarify the function of BPAG1 in melanoma and the mechanism of
auto-antibody creation. These studieswillbefundamentalinassessing
whether BPAG1 auto-antibodies can have an impact on improving
the prognosis of melanomas.
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stage
total sample
number
BPAG1 auto-antibody
positive %
early 18 6 33.3
advanced 37 7 18.9
total 55 13 23.6
The maximum INDEX value in healthy volunteers (4.64) was defined as the cut off
level. The patients were classified by using the American Joint Committee on Cancer
(AJCC)2002stagingcriteria.Insitu,stageIorstageIIpatientswereclassifiedas‘‘early’’,
while stage III or stage IV patients were classified as ‘‘advanced’’.
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